These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 6115735)

  • 1. Apomorphine in schizophrenia.
    Hollister LE; Davis KL; Berger PA
    Commun Psychopharmacol; 1980; 4(4):277-81. PubMed ID: 6115735
    [No Abstract]   [Full Text] [Related]  

  • 2. Apomorphine's antipsychotic activity.
    Schaffer MH; Davis JM; Tamminga CA
    Arch Gen Psychiatry; 1985 Sep; 42(9):927-8. PubMed ID: 2864035
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel drug treatments for schizophrenia.
    Hollister LE
    Psychopharmacol Bull; 1987; 23(1):82-4. PubMed ID: 2885891
    [No Abstract]   [Full Text] [Related]  

  • 4. Apomorphine reduces schizophrenic symptoms.
    Schaffer MH; Tamminga CA; Smith RC; Davis JM
    Psychopharmacol Bull; 1980 Jan; 16(1):55-7. PubMed ID: 6987694
    [No Abstract]   [Full Text] [Related]  

  • 5. [FDA phase II and phase III drug evaluation of antipsychotic agents].
    Yagi K
    Seishin Shinkeigaku Zasshi; 1990; 92(9):584-92. PubMed ID: 1980369
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of intravenous and subcutaneous administration of apomorphine on the clinical symptoms of chronic schizophrenics.
    Syvälahti EK; Säkö E; Scheinin M; Pihlajamäki K; Hietala J
    Br J Psychiatry; 1986 Feb; 148():204-8. PubMed ID: 3516291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ICI 204,636: a new atypical antipsychotic drug.
    Hirsch SR; Link CG; Goldstein JM; Arvanitis LA
    Br J Psychiatry Suppl; 1996 May; (29):45-56. PubMed ID: 8733823
    [No Abstract]   [Full Text] [Related]  

  • 8. Celecoxib augmentation of continuously ill patients with schizophrenia.
    Rapaport MH; Delrahim KK; Bresee CJ; Maddux RE; Ahmadpour O; Dolnak D
    Biol Psychiatry; 2005 Jun; 57(12):1594-6. PubMed ID: 15953498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interaction between superoxide dismutase and prolactin is involved in response to haloperidol and risperidone treatment in schizophrenia: a double-blind and randomized study.
    Zhang XY; Zhou DF; Cao LY; Wu GY; Shen YC
    J Clin Psychopharmacol; 2006 Feb; 26(1):103-5. PubMed ID: 16415724
    [No Abstract]   [Full Text] [Related]  

  • 10. Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study.
    Stryjer R; Strous R; Bar F; Shaked G; Shiloh R; Rozencwaig S; Grupper D; Buchman N; Kotler M; Rabey JM; Weizman A
    Hum Psychopharmacol; 2004 Jul; 19(5):343-6. PubMed ID: 15252826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.
    Assion HJ; Reinbold H; Lemanski S; Basilowski M; Juckel G
    Pharmacopsychiatry; 2008 Jan; 41(1):24-8. PubMed ID: 18203048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapse prevention in schizophrenia: evidence from longterm, randomized, double-blind clinical trials.
    Pecenak J
    Neuro Endocrinol Lett; 2007 Feb; 28 Suppl 1():49-70. PubMed ID: 17262007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apomorphine and schizophrenia.
    Johns CA; Levy MI; Davis BM; Mohs RC; Kendler KS; Mathe AA; Trigos G; Horvath TB; Davis KL
    Psychopharmacol Bull; 1984; 20(1):103-7. PubMed ID: 6718635
    [No Abstract]   [Full Text] [Related]  

  • 14. Newer antipsychotics similar to older agents.
    J Fam Pract; 2005 Dec; 54(12):1026. PubMed ID: 16370079
    [No Abstract]   [Full Text] [Related]  

  • 15. Hormonal response to dehydroepiandrosterone administration in schizophrenia: findings from a randomized, double-blind, placebo-controlled, crossover study.
    Strous RD; Gibel A; Maayan R; Weizman A; Ritsner MS
    J Clin Psychopharmacol; 2008 Aug; 28(4):456-9. PubMed ID: 18626277
    [No Abstract]   [Full Text] [Related]  

  • 16. Growth hormone responses to graded doses of apomorphine HCl in schizophrenia.
    Cleghorn JM; Brown GM; Brown PJ; Kaplan RD; Mitton J
    Biol Psychiatry; 1983 Aug; 18(8):875-85. PubMed ID: 6137249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biological methods of predicting the effectiveness of psychopharmacologic treatment of schizophrenia (review)].
    Nemtsov AV; Kalinin VV
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1981; 81(8):1232-41. PubMed ID: 6171962
    [No Abstract]   [Full Text] [Related]  

  • 18. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of higher-dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients].
    Schmidt LG; Schüssler G; Kappes CV; Müller-Oerlinghausen B
    Nervenarzt; 1982 Sep; 53(9):530-6. PubMed ID: 6127637
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comparative effectiveness of flupenthixol and risperidone on negative symptoms of schizophrenia].
    Philipp M; Lesch OM; Schmauss M; Dose M; Glaser T
    Psychiatr Prax; 2003 May; 30 Suppl 2():S94-6. PubMed ID: 14509050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.